Phase II trial of temsirolimus alone and in combination with irinotecan forKRASmutant metastatic colorectal cancer: Outcome and results ofKRASmutational analysis in plasma-Reference-Cited by-同舟云学术

Phase II trial of temsirolimus alone and in combination with irinotecan forKRASmutant metastatic colorectal cancer: Outcome and results ofKRASmutational analysis in plasma

Published:2013-03-20 Issue:5 Volume:52 Page:963-970
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Spindler Karen-Lise G.,Sorensen Morten M.,Pallisgaard Niels,Andersen Rikke F.,Havelund Birgitte M.,Ploen John,Lassen Ulrik,Jakobsen Anders K. M.

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/0284186X.2013.776175

Reference23 articles.

1. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

2. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies

3. Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical Trials

4. mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer

5. Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment;International Journal of Molecular Sciences;2024-03-09

2. Oncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression;Cancer Discovery;2023-09-27

3. KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics;Critical Reviews in Oncology/Hematology;2023-06

4. UBXN2A suppresses the Rictor-mTORC2 signaling pathway, an established tumorigenic pathway in human colorectal cancer;Oncogene;2023-04-10

5. Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation;Cancers;2023-02-25